ARTICLE | Clinical News

Revimid: Phase I/II

December 17, 2001 8:00 AM UTC

In an open-label U.S. Phase I/II trial of Revimid in 24 patients with refractory MM, 19 patients (79%) achieved stable disease or better, and 63% of patients had >25% reductions in paraprotein, a marker of tumor load. CELG said that 16 of the patients had failed prior Thalomid thalidomide therapy, which is used off-label for myeloma. CELG said no dose limiting toxicities were seen, but during the trial extension, when patients were maintained on the same doses used in the randomized phase, dose reduction was required for grade 3 thrombocytopenia and grade 3/4 neutropenia in several patients taking the highest dose. ...